Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

Sanghamitra Saha headshot

Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Top Ranked Income Stocks to Buy for May 22nd

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 22nd.

Top Ranked Income Stocks to Buy for May 21st

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 21st.

AbbVie's Brain Cancer Candidate Fails in Phase III Study

AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL

Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock

AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

AbbVie Settles Humira Litigation With Boehringer Ingelheim

AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

Top Ranked Income Stocks to Buy for May 8th

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 8th.

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Top Ranked Income Stocks to Buy for May 6th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 6th.

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products

The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products

Mark Vickery headshot

Top Stock Reports for Facebook, Comcast & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Comcast (CMCSA) and AbbVie (ABBV).

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Upgraded to Buy: Here's Why

AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV)

AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View

AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up

AbbVie's (ABBV) first-quarter 2018 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

Kinjel Shah headshot

Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.

Kinjel Shah headshot

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.

Tracey Ryniec headshot

5 Turnaround Earnings Charts You Must See

They were once some of the hottest stocks on the Street. Are they returning to greatness?